Study summary
Immunotherapy before surgery cleared more tumors
28% vs 5%of tumors fully cleared before surgery
What was tested
Camrelizumab, a PD-1 immunotherapy, added to chemotherapy before surgery, compared with chemotherapy alone.
What they found
- No living cancer was found at surgery in 28.0% and 15.4% of people in the two camrelizumab groups, vs 4.7% with chemotherapy alone.
- Serious side effects were similar across groups: 34%, 29% and 29%.
- Whether this means living longer was not yet known when published.
What it means
Strong evidence that immunotherapy before surgery shrinks tumors more. The survival answer is still pending.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.